gdc-0449 and Margins-of-Excision

gdc-0449 has been researched along with Margins-of-Excision* in 2 studies

Trials

1 trial(s) available for gdc-0449 and Margins-of-Excision

ArticleYear
A randomized phase II study evaluating vismodegib as neoadjuvant treatment of basal cell carcinoma preceding Mohs micrographic surgery: results and lessons learned.
    The British journal of dermatology, 2019, Volume: 181, Issue:1

    Topics: Anilides; Biopsy; Carcinoma, Basal Cell; Female; Humans; Male; Margins of Excision; Mohs Surgery; Neoadjuvant Therapy; Proof of Concept Study; Pyridines; Skin; Skin Neoplasms; Treatment Outcome

2019

Other Studies

1 other study(ies) available for gdc-0449 and Margins-of-Excision

ArticleYear
Vismodegib as Eye-Sparing Neoadjuvant Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
    Journal of drugs in dermatology : JDD, 2021, May-01, Volume: 20, Issue:5

    Locally-advanced periocular basal cell carcinoma (BCC) pose many therapeutic challenges due to the need to preserve functionality and cosmesis of the orbit and periocular area. Surgical excision and subsequent orbital exenteration are two recognized modalities of treatment. Vismodegib is currently an FDA-approved monotherapy for locally-advanced and metastatic BCC. We present a case of the use of vismodegib as neoadjuvant therapy prior to surgical excision of a locally-advanced periocular recurrent BCC in a 75-year-old male. The patient’s tumor successfully responded to vismodegib allowing surgical excision with clear margins. The orbit was saved in a patient who otherwise would have required complete orbital exenteration. J Drugs Dermatol. 20(5):552-554. doi:10.36849/JDD.5661.

    Topics: Administration, Oral; Aged; Anilides; Carcinoma, Basal Cell; Eyelid Neoplasms; Eyelids; Humans; Magnetic Resonance Imaging; Male; Margins of Excision; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organ Sparing Treatments; Pyridines; Skin Neoplasms; Treatment Outcome

2021